Physician profile
Albin Oh
NPI 1316478332
$2,990.08
in general payments reported to CMS, 2019-2025
20 companies · $796 in 2025
The $796 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $180 · 2023: $943 · 2024: $1,071 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,624 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,623.83 |
| Education | $186.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $390.90 | 2022-2025 | |
| Astellas Pharma US INC | $390.58 | 2024-2025 | Veozah |
| Inspire Medical Systems, INC. | $331.59 | 2023-2024 | Inspire |
| Pfizer INC. | $310.87 | 2022-2025 | |
| Novo Nordisk INC | $236.61 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $226.41 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $195.43 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $191.44 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $159.15 | 2023-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $139.76 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Dexcom, INC. | $111.08 | 2022-2023 | Dexcom G6 Transmitter |
| Tris Pharma INC | $93.87 | 2024-2025 | Dyanavel Xr |
| Exact Sciences Corporation | $48.24 | 2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $41.34 | 2022-2023 | Rexulti |
| Shield Therapeutics INC | $29.72 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik Nro, INC. | $26.17 | 2024 | Prospera |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.20 | 2025 | Xifaxan |
| Antares Pharma, INC. | $17.38 | 2024 | Xyosted |
| Medtronic, INC. | $17.10 | 2025 | Venaseal |
| Currax Pharmaceuticals LLC | $13.24 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albin Oh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.